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ABSTRACT 
Objective: A simple, economical, robust and stability-indicating reverse phase high performance liquid chromatography method was developed and 
validated for the quantification of ropinirole hydrochloride in API and tablets to achieve shorter retention time, to minimize human error by 
avoiding the use of buffers and weighing procedure and analyze more number of samples in shorter period of time with good accuracy.  
Methods: The chromatographic conditions for separation of ropinirole hydrochloride was carried out using Gemini NX C18 column (15 cm x 4.6 
mm), 5 µm particle size with the mobile phase composing of methanol: acetonitrile (70:30 v/v), delivered at flow rate 0.7 ml/min and UV detection 
wavelength at 250 nm.  
Results: The retention time was observed at 2.718 min. The system suitability results were found to be within limits. The method was precise, with 
lower than 2 %RSD and the calibration curve was linear (r2=1) over a concentration range of 2.5-160 µg/ml. The detection and quantification limit was 
found to be 0.045 µg/ml and 0.15 µg/ml, respectively. Recovery of the drug was found between 100.09-100.19%. The assay of ropinirole hydrochloride 
in ROPITOR® and ROPARK®
Conclusion: The low coefficient of variation and agreeable recovery confirmed that the newly developed method could be employed for routine 
analysis of ropinirole hydrochloride in API and tablets. 
 tablets were found to be 100.4 and 103.60 %, respectively. The forced degradation studies were carried out to demonstrate 
the specificity of the method by exposing the API under conditions of hydrolysis, oxidation, thermal and photolytic as per ICH Q1A(R2) guidelines.  
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Ropinirole hydrochloride (RH) is the hydrochloride salt form of 
ropinirole, a non-ergot dopamine agonist with antiparkinson 
property [1], acting as a substitute for dopamine, ropinirole acts as 
a D2, D3 and D4 dopamine receptor agonist with more affinity for 
D2. It is weakly active at the 5-HT2, and α2 receptors [2]. Chemically 
RH is a 4-[2-(dipropylamino) ethyl]-1,3-dihydro-2H-indol-2-one, 
hydrochloride (fig. 1). The molecular formula and weight of RH are 
C16H24N2O. HCl and 296.84 g/mol, respectively. The pKa and water 
solubility was found to be 10.17 and 133 mg/ml [3]. It is available in 
both conventional and extended-release tablet dosage form in the 
dose range from 0.25 mg up to 6 mg [4]. It is prescribed for the 
treatment of parkinson’s disease and restless legs syndrome [5]. 
 
 
Fig. 1: Chemical structure of RH (Molecular formula: C16H24N2O. 
HCl) 
 
Literature survey reveals that different spectroscopic methods have 
been reported for the estimation of RH using UV-Visible 
spectrophotometry [6], liquid chromatography (HPLC) with UV 
detector [7-9], PDA detector [10], ECD detector [11], high 
performance thin layer chromatography [12, 13] and LC-ESI-MS/MS 
coupled to tandem mass spectrometry with electrospray ionization 
[14]. Among them, reported HPLC analytical methods in the 
literature for quantifying RH in API and its formulation has either 
had longer retention time or have tedious analytical procedures or 
not developed stability-indicating analytical procedure.  
The objective of the present study was to develop a new, simple, 
rapid, precise, accurate and stability-indicating RP-HPLC to quantify 
RH in API and tablet dosage form together with its validation study 
[15, 16]. This work describes the validation parameters stated by the 
FDA [17] and ICH guidelines [18]. With the initiation of the ICH 
Q1A(R2) guidelines, requirements for the establishment of stability 
indicating methods have been ever more clearly mandated [19]. The 
guidelines explicitly require the conduct of forced degradation 
studies under a variety of conditions like hydrolysis (acid and 
alkaline), oxidation, photolytic and thermal, etc. and separation of 
drug from degradation products [20, 21]. 
MATERIALS AND METHODS 
Chemicals and reagents 
A working reference standard (100.07 %) and API (100 %) of RH was 
obtained as a gift sample from Alembic Pharmaceuticals Ltd., 
Vadodara, Gujarat, India. HPLC grade methanol and acetonitrile 
solvents were purchased from Merck Specialities Pvt. Ltd. Mumbai, 
India. ROPITOR® 0.5 mg (Torrent Laboratories Pvt. Ltd.) and 
ROPARK® 0.5 mg (Sun Pharmaceuticals Industries Ltd.) tablets were 
procured from a local pharmacy. HPLC grade water was produced 
using a Millipore water purification system. AR grades of hydrochloric 
acid (HCl), hydrogen peroxide (H2O2) and sodium hydroxide (NaOH) 
used were purchased from S D Fine Chem Limited, Bengaluru. Class-A 
glassware was used throughout the experiments. 
Instrumentation and chromatographic conditions 
The instrument used and optimized chromatographic conditions for 
the determination of RH is given in table 1. Other equipment used was 
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UV-Visible spectrophotometer (LAMBDA™365, ParkinElmer Inc. USA), 
Analytical balance (Mettler Toledo, USA), Hot air oven and Digital 
ultrasonic water bath (Servewel instruments). A mixture of methanol: 
acetonitrile (70:30 v/v) was used as a mobile phase which was filtered 
through 0.45 µm finer porosity nylon membrane filter, degassed prior 
to use using a digital ultrasonic water bath. 
 
Table 1: Instrumentation and chromatographic conditions 
Parameter Instrument and optimized chromatographic conditions 
Instrument High-performance liquid chromatography, Shimadzu-LC-20AD Prominence, Lab Solutions software was used for data 
acquisition and system suitability calculations. 
Column Phenomenex, Gemini NX C18 Column (15 cm X 4.6 mm) 5 µm particle size 
Detector UV Detector 
Wavelength 250 nm 
Injection volume 20 µl 
Flow rate 0.7 ml/min 
Mobile phase Methanol: acetonitrile (70:30 v/v) 
Diluent Mobile phase 
Mode of operation Isocratic elution 
 
Preparation of standard and sample solution 
The primary stock solution was prepared by dissolving API 
equivalent to 20 mg in 100 ml mobile phase, to get a concentration 
of 200 µg/ml. 1 ml of the primary stock solution was further diluted 
to 10 ml with the mobile phase to get a final concentration of 20 
µg/ml (secondary stock solution). The absorbance of the secondary 
stock solution (20 µg/ml) was scanned in the range of 200 to 300 
nm using a mobile phase as blank by UV-Visible spectrophotometer 
to select the detection wavelength. The sample solution was 
prepared by weighing twenty tablets from each product and their 
average weight was calculated, tablets were finely powdered. Tablet 
powder equivalent to 2 mg RH was weighed and transferred into a 
100 ml volumetric flask containing 75 ml mobile phase, sonicated 
for 30 min with intermittent shaking to completely dissolve. Allowed 
to cool to room temperature and then made up the volume with the 
mobile phase to get a final sample concentration of 20 µg/ml. The 
above secondary stock solution and sample solutions were filtered 
through 0.45 µm nylon membrane (Millipore) syringe filter before 
injection.  
Analysis of RH in marketed tablets 
The developed method was used to estimate the total amount of 
drug present in commercially available tablets. The analysis was 
done by injecting API and sample drug solutions into the HPLC 
system (n=3) and the peak area count was recorded. Determine the 
amount of drug present in each marketed tablet samples.  
Method validation 
The developed method has been validated as per the USP and ICH 
guidelines includes system suitability, specificity, precision (system 
repeatability, method repeatability and intermediate precision) 
linearity, range, LOD and LOQ, stability of analytical solution, 
accuracy and robustness [17, 18, 23].  
System suitability 
The suitability of the system was tested by injecting the secondary 
stock solution into HPLC system as six replicates. The tailing factor 
for the RH peak from the first injection should be less than 2 and the 
column efficiency determined from the RH peak from the first 
injection should not be less than 2000 theoretical plates. The RSD for 
the mean peak area calculated from the six replicate injections of RH 
should be lower than 2 % [23]. 
Specificity and forced degradation studies 
Specificity consisted of interference of blank (mobile phase). It was 
carried out by injecting six replicates of the mobile phase into the 
HPLC system to check the interference of any peak at the main peak 
of the analyte [22].  
Forced degradation study was carried to give information about the 
degradation behavior of analyte in the presence of its degradation 
products during stress conditions. The API was subjected to 
hydrolysis (acid and alkali), oxidative, thermal and photolytic stress 
conditions [20, 21]. To assess the stress testing for acid hydrolysis, 
alkali hydrolysis, and oxidative studies by taking each 5 ml of 
primary stock solution (200 µg/ml) was transferred into three 50 ml 
volumetric flasks. Then the solution was mixed with 5 ml of 0.1N 
HCl, 5 ml of 0.1N NaOH and 5 ml of 3 % hydrogen peroxide was 
added to each volumetric flask. The prepared solutions were heated 
at 80 °C for 2 h in a boiling water bath, cooled to room temperature 
with intermittent shaking. These solutions were neutralized with an 
amount of acid or base equivalent to that of the previously added 
and then the volume was made up to the mark with mobile phase to 
get a concentration of the secondary stock solution. To assess the 
stress testing for thermal condition API was exposed to a 
temperature of 80 °C for 48 h in a hot air oven. 20 mg of API dried 
powder was  weighed and transferred to a 100 ml volumetric flask 
containing 75 ml of mobile phase, dissolve and then volume is made 
up to the mark with the same, to get a concentration of 200 µg/ml, 1 
ml of the above solution was further diluted to 10 ml with the mobile 
phase to get a final concentration of 20 µg/ml. Photolytic stress 
testing the secondary stock solution (20 µg/ml) was exposed to UV 
light (254 nm) for 72 h. Inject the resultant solution of all stress 
condition samples into the HPLC system, record the chromatograms 
to assess the degradation behavior of API during stress testing. 
Precision 
The precision of an analytical method is the closeness of agreement 
among individual test results when the method is applied repeatedly 
to multiple sampling of a homogenous sample. The precision of an 
analytical method is usually expressed in terms of RSD. In precision 
study system repeatability, method repeatability and intermediate 
precision have been carried out. The system and method repeatability 
were examined by analyzing API solution (20 µg/ml) in six replicates. 
%RSD of area counts of RH peak was calculated. Intermediate 
precision (Ruggedness) is carried out within the laboratory under 
different sets of conditions. Six replicates of API was injected into the 
HPLC system by different analysts, on different days (intraday-
repeated for six replicates were injected at every h up to 12 h in the 
same day and interday-repeated six replicates for 3 d), on different 
instruments. %RSD for each condition was calculated.  
Linearity, range 
Linearity and range were established from the standard stock 
solution, a series of solutions were prepared at concentration levels 
ranging from 2.5 to 160 µg/ml of the standard solution. The peak 
area responses of solutions at all levels in six replicates were 
measured. The area count versus concentration data was treated by 
linear regression analysis and the linearity of response to RH was 
determined by calculating the correlation coefficient (acceptance 
criterion of correlation coefficient shall not be less than 0.997).  
LOD and LOQ 
The LOD and LOQ were determined by visual evaluation by 
preparing the lowest dilution of API solution, injected into the HPLC 
system and the response obtained was recorded. 
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Stability of the analytical solution 
The stability of the analytical solution was performed by preparing 
20 µg/ml concentrations of API and sample (tablets) solutions. Both 
the solutions were kept at room temperature and analyzed at time 
intervals of 0, 24, 48 and 72 h. Six replicates of the API and sample 
solutions were injected into the HPLC system. The corresponding 
area counts for API and sample solutions were measured. Calculated 
the cumulative %RSD (acceptance criterion: cumulative %RSD shall 
not be more than 2). 
Accuracy 
Accuracy study, known concentration of the sample (10µg/ml) were 
taken separately into three set of nine volumetric flasks and spiked 
with known concentration of API at three different levels at 75 % 
(Level 1), 100 % (Level 2) and 125 % (Level 3) of sample 
concentration in triplicates. The prepared solutions were analyzed by 
injecting six replicates of each set in each level into the HPLC system 
and calculate the percentage amount of API recovered in spiked 
sample and %RSD in each level (acceptance criterion: %recovery shall 
be in the range of 98-102 and %RSD shall not be more than 2.0). 
Robustness 
The robustness of an analytical method is used to measure its capacity 
to remain unaffected by small but deliberate variations in methods 
parameters and provides an indication of its reliability during normal 
usage. The robustness of the developed method was determined by 
changing the instrumental conditions flow rate (±0.07 ml/min), 
detection wavelength (±2 nm) and composition of the mobile phase 
(±5 v/v). System suitability parameters such as retention time, tailing 
factor, % RSD of area counts and theoretical plates of the standard 
solution was checked at each variable condition. The amount of drug 
recovered for each instrumental condition was calculated. The overall 
%RSD between the data and the amount of drug recovered at each 
variable condition (acceptance criterion: system suitability should 
pass, overall %RSD shall not be more than 2.0 and the amount of drug 
recovered should be less than±10 %). 
RESULTS AND DISCUSSION 
HPLC method development and finalization 
The maximum absorbance (λmax) of RH was found to be 250 nm in 
mobile phase using UV-Visible spectrophotometer. The spectrum is 
shown in fig. 2. This wavelength was chosen for the detection of RH. 
Several researchers earlier reported HPLC analytical methods for 
estimation of ropinirole hydrochloride in bulk and its 
pharmaceutical dosage form by varying the mobile phase 
composition, flow rate and stationary phase (column) to elute the 
RH. The RP-HPLC analytical method developed consists of a mobile 
phase phosphate buffer (pH 6) and acetonitrile (50:50 v/v), at a flow 
rate 0.5 ml/min stationary phase using C18 column 250 x 4.6 mm, 5 
μm particle size in isocratic mode and the total run time was 15 min 
achieved the retention time of 4.867 min [8]. RP-HPLC method 
developed with mobile phase comprising of acetate buffer (0.05 mol 
glacial acetic acid, pH 3):acetonitrile in the ratio of 50:50 v/v, at a 
flow rate 1 ml/min using the column C18 Hypersil BDS (250 x 4.6 
mm, 5 μm) at 250 nm, the analyte elutes at retention time of 4.037 
min and running time is 14 min [7]. For the determination of 
impurities present in ropinirole tablets, the following HPLC 
analytical method was developed with retention time 26.80 min. 
Two sets of mobile phases were employed, A (mixture of potassium 
dihydrogen phosphate buffer (19.6 mmol):acetonitrile (98:2 v/v), 
adjust pH 7 using triethylamine) and B (acetonitrile) for enhancing 
the peak resolution. The flow rate was maintained during the 
analysis was 1 ml/min, the stationary phase used was Kromasil C8 
(250 x 4.6 mm, 5 μm). The detector adopted was DAD detector and 
the mode of operation was in low-pressure gradient [10]. Another 
analytical method by RP-HPLC was developed to estimate 
simultaneously by ropinirole hydrochloride and its base by using a 
mobile phase acetonitrile: phosphate buffer (55:45 v/v) of pH 6 
adjusted by adding 0.3 % triethanolamine solution. The flow rate 
was 1 ml/min. The stationary phase was Kromasil C18 (250 x 4 mm) 
to achieve retention time for ropinirole hydrochloride and its base 
ropinirole was 7.70 and 5.04 min, respectively [9]. Further one more 
method was developed for RH were in an ECD detector was adopted. 
The mobile phase comprises of methanol: 50 mmol sodium 
dihydrogen phosphate(10:90v/v), and its pH was adjusted with 
diethylamine to 4.5, the shorter stationary phase was Chromolith 
RP-18e (100 x 4.6 mm) to achieve 2.38 min as retention time and 
flow rate maintained was 2 ml/min [11]. To summarize the results 
with respect to the retention time and composition of the mobile 
phase from the above methods, retention time varies from 3.987 min 
to 26.80 min and with a shorter column length and high flow rate 
retention time was 2.85 min. Suggested that the developed methods 
were not economical since consumption of the mobile phase was 
directly proportional to retention time and as retention time was 
more in the above methods also lead less turnout of the samples 
makes these methods were not economical. The preparation of 
various mobile phases which were used in the above available 
methods includes weighing and use of buffers for adjustment of pH 
contributes to the inclusion of errors during the mobile phase 
preparation. The objectives of the present study were to develop RP-
HPLC method to achieve shorter retention time, more turnout of the 
sample, less utilization of mobile phase and error-free procedure 
adopted to achieve economical method. The chromatographic 
method was developed by several trials were taken in order to 
finalize the chromatographic conditions. Various mobile phase 
composition with different pH was tried to elute the drug. The short 
retention time with a sharp peak of the analyte was dependent on 
the percentage of methanol and acetonitrile. Finally, the novel 
method was developed to quantitative estimation of RH in API and 
tablets consists of mobile phase methanol: acetonitrile (70:30 v/v) 
with Phenomenex, Gemini NX, C18 column (15 cm x 4.6 mm, 5 µm) 
stationary phase, at a flow rate of 0.7 ml/min with a short runtime of 
7 min. The retention time was found to be 2.718 min and this above-
developed method yields satisfactory separation, stable baseline and 
sharp symmetrical peak with satisfactory system suitability results. 
A typical chromatogram of RH and placebo obtained by using the 




Fig. 2: UV-Visible spectra of RH in mobile phase (30 µg/ml), x-axis=Wavelength (nm) and y-axis=Absorbance 
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Fig. 3: HPLC Chromatogram and system suitability of RH at 250 nm (30 µg/ml) 
 
 
Fig. 4: HPLC Chromatogram of placebo at 250 nm 
 
Analysis of RH in marketed tablets 
The amount of RH present in each product of ROPITOR® and 
ROPARK® marketed tablets were found to be 0.502 mg and 0.518 
mg, respectively. This is equivalent to 100.4 to 103.6 percent of the 
label claim. The determined %assay of RH in both the tablets were 
found within the USP acceptance limits (90-110 %). The results 
show that there was no interference of excipients and impurities 
was observed in samples for the developed method.  
Method validation 
During the method validation study, known concentration of the 
standard solution was injected on different days. Using the LC 
solution software, retention time, theoretical plates and tailing 
factor for RH peak was recorded. %RSD for six replicates was 
calculated. The retention time, theoretical plates (N) and tailing 
factor for the RH from the API were found to be 2.718 min, 3646.257 
and 1.310, respectively. The RSD for the mean peak area count 
calculated from the six replicates was found to be 0.097%. This 
indicates that the method is suitable. The above three system 
suitability parameters were met during the course of entire 
validation.  
Specificity and forced degradation studies 
The result of the specificity study indicates that there are not any co-
eluting peaks from the blank (mobile phase) at the retention time of 
the analyte proved the specificity of the developed method. In forced 
degradation studies the RH was found to be degrading in acidic, 
alkaline and oxidative stress conditions. The RH solution heated 
with 0.1N HCl at 80 °C for 2 h showed 1.50 % degradation. 
Degradation peaks in acidic stress condition were observed at 3.63. 
3.96 and 6.66 min. The RH solution heated with 0.1N NaOH at 80 °C 
for 2 h showed 3.60 % degradation. The degradation peaks in 
alkaline stress condition were observed at 4.12 and 4.48 min. The 
RH solution in oxidative stress condition (3 % H2O2 to heat at 80 °C 
for 2 h) was observed 3.2 % degradation. The degradation peaks in 
oxidative stress condition were observed at 3.66 and 4.13 min. 
During thermal degradation (exposed to 80 °C for 48 h) and photo 
degradation (exposed to UV light for 72 h), the chromatogram did 
not show the appearance of any degradation peak. Typical chro-
matograms obtained for RH under different conditions are shown in 
fig. 5. From the forced degradation study, it can be concluded that 
RH peak obtained by analysis of API in all the stress condition was 
homogenous, pure and unchanged by the presence of its degradation 
products, confirming the stability indicating nature of the method. 
Hence, the developed method is able to quantify RH in the presence 
of its degradation products. 
Precision 
The HPLC system and developed method have an acceptable level of 
precision. The system and method repeatability were found to be 
precise as the %RSD of peak area counts for six replicates was found 
to be 0.349 and 0.532, respectively. In intermediate precision, the 
individual and overall %RSD under the different analytical 
procedure and laboratory conditions were found to be less than 2. 
The results reveal that the newly developed method was rugged. 
The precision data are tabulated in table 2. 
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Fig. 5: HPLC Chromatograms showing forced degradation studies of RH under various stress conditions, x-axis=min and y-axis=peak area 
count (mV). Chromatograms showing API (A), acid degradation (B), alkaline degradation (C), oxidative degradation (D), thermal 
degradation (E) and photolytic degradation (F) studies 
 



























Peak area Peak area 
1 1112707 1134189 1 1216773 1 1150322 1143874 1138905 1019233 1112886 
2 1121213 1137256 2 1219542 2 1170165 1158275 1142407 1017847 1110686 
3 1120612 1132983 3 1204308 3 1148159 1149481 1141323 1025641 1110498 
4 1119116 1137629 4 1204323  1154487 1138001 1016798 1110167 
5 1118148 1147987 5 1211827 1137829 1143322 1021178 1110533 
6 1124416 1145244 6 1214152 1155630 1133875 1015161 1112064 
12 1212006 
Mean 1119369 1139215  1211847  1156215 1149929 1139639 1019310 1111139 
SD 3908 6062  5806  12129.08 7826 3479 3721 1080.347 
%RSD 0.349 0.532  0.479  1.049 0.681 0.305 0.365 0.097 
*Results obtained in different analysts by a different instrument, SD stands for standard deviation of six replicates. 
 
Linearity, range 
The regression equation from peak area count versus concentration 
data (fig. 6) obtained y=57411x+4867 and correlation coefficient 
(r2) was 1, indicating that the response is linear over the specified 
range of 2.5-160 µg/ml. The results are shown in table 3. 
LOD, LOQ and stability of the analytical solution 
The LOD and LOQ for RH were found to be 0.045 µg/ml and 0.15 
µg/ml, respectively. It reveals that the developed method was more 
sensitive [24]. The cumulative %RSD of the API and sample solution 
was found to be 0.87 and 0.82, respectively, at room temperature. 
The determined cumulative %RSD of API and sample solution of RH 
was well within the limits of 2.0 %. It reveals that API and sample 
are stable in solution up to 72 h at room temperature. 
Accuracy 
Recovery studies of three samples in three concentration levels 
ranging from 75 to 125 % were determined. The individual and 
overall percentage recovery and %RSD of the API were found within 
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the acceptance criteria, it was found that the percent recovery value 
of the API from the reanalyzed solution of the formulation was 
between 98 to 102. This indicates that the method is accurate and 
also reveals that commonly used excipients and additives in the 
tablet formulation were not interfering in the developed method. 
The results are given in table 4. 
  
 
Fig. 6: Calibration curve of RH (y= 57411x+4867, r2= 1), (*n=6) 
 
Table 3: Summary of regression analysis of the calibration curve 
Parameters Results Acceptance Criteria 
Linearity Range (µg/ml) 2.5-160 - 
Regression equation (y=mx+c) y=57411x+4867 - 
Correlation co-efficient (r2) 1.0 Not less than 0.997 
Percentage curve fitting 99.9% Not less than 99% 
Intercept (c) 4867 - 
Slope (m) 57411 - 
 

















75 10 5 862928 5.000 100.01 100.17 0.470 
10 5 865633 4.998 99.95 
10 5 864490 5.025 100.55 
100 10 10 1157061 10.113 101.13 100.19 0.531 
10 10 1160680 10.760 99.76 
10 10 1154523 10.069 100.69 
125 10 15 1451613 14.934 99.56 100.09 0.135 
10 15 1453342 15.264 100.76 
10 15 1458129 14.993 99.95 
Six replicates of 3 observations (n=3) in each level 
 











0.63 0.77 248 252 65:35 75:25 
Retention time (min) 2.874 3.437 2.975 2.972 2.984 2.758 2.644 
Tailing factor 1.310 1.494 1.479 1.173 1.508 1.173 1.196 
RSD (%) 0.532 0.433 0.121 0.179 0.295 0.696 0.616 
Theoretical plate(#) 3646 2897 3127 2975 3614 3162 3098 
Amount of drug recovered (%) 102.55 106.98 95.86 98.83 98.20 95.71 97.84 
*Mobile phase: methanol: acetonitrile (70:30 v/v), column: Gemini NX C18-Phenomenex, detection wavelength: 250 nm, flow rate: 0.7 ml/min and 
injection volume: 20 μl. 
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With all the deliberate varied chromatographic conditions (flow rate, 
wavelength of detection and composition of the mobile phase). The 
results obtained were well within the limit, which proves the robustness 
of the method. The results of robustness data are given in table 5. 
CONCLUSION 
The present work, stability-indicating RP-HPLC method was 
developed for the quantitative estimation of RH in API and tablets is 
simple, rapid, economical, precise and accurate. The method has 
been validated and satisfactory results were found in all the tested 
validation parameters. The retention time was found to be 2.718 
min due to this the method require less time, the consumption of the 
mobile phase is less. Preparation of the mobile phase involves no 
weighing procedures and use of buffers thereby reduces the human 
and instrumental error and increase the efficacy of the method as 
compared with the earlier reported HPLC-UV/DAD/ECD methods. 
The API and sample solution was stable up to 72 h at room 
temperature. The results of the stress testing reveal that the method 
is specific and there is no other co-eluting peak with the RH main 
peak. Hence, the developed method can be conveniently used for 
determining the quality control of RH in API and tablets. 
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